Back to Search
Start Over
AstraZeneca's Calquence receives Japanese approval for adult patients with treatment-naive CLL
- Source :
- PharmaBiz. December 29, 2022
- Publication Year :
- 2022
-
Abstract
- AstraZeneca's Calquence (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naȯve chronic lymphocytic leukaemia (CLL) (including small lymphocytic [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.731566229